medigraphic.com

2020, Number 2

<< Back Next >>

Cuba y Salud 2020; 15 (2)

Parkinson’s disease: neurodegeneration associated with Oxidative Stress

Fernández GJJ, Granados HI

Language: Spanish
References: 46
Page: 45-52
PDF size: 603.21 Kb.


ABSTRACT

Objetivo: to describe the association between oxidative stress and Parkinson’s disease.
Development: a documentary review was carried out in Scientific Databases, to clarify the pathophysiological mechanism of Parkinson’s disease. This is the second most common neurodegenerative disorder among people over the age of 65; it is conditioned by a number of factors that precipitate its appearance; oxidative stress was highlighted as the mechanism that precedes neuronal death, genetic mutations in protein synthesis that reduce the antioxidant responses of the cell, as well as the reduction in the function of the ubiquitin proteasome system, and induction of oxidative stress by reactive oxygen species and the accumulation of free radicals.
Conclusions: the multifactorial approach persists as a promising option to understand the pathophysiology of Parkinson’s disease; The relationship that may exist between oxidative stress and prion theory presents a new panorama around a possible onset of Parkinson’s disease away from the brain and the risk factoroxidative stress relationship is one of the paths that can be taken. to clarify the origin of this disease.


REFERENCES

  1. Pretorius E, Swanepoel A, Buys A, Vermeulen N, Duim W, Kell D. Eryptosis as a marker of Parkinson’s disease. Aging. 2014; 6 (10): 788-819 https://doi.org/10.18632/aging.100695

  2. Xu J, Gong DD, Man CF, Fan Y. Parkinson’s disease and risk of mortality: meta-analysis and systematic review. Acta neurologica Scandinavica. 2014; 129:71-79.

  3. Pavón Fuentes N, Lorigados Pedre L. Neuroinflamación y Enfermedad de Parkinson. Rev Panorama. Cuba y Salud [Internet]. 2019 [citado]; 14(3):44-49. Disponible en: http://www.revpanorama.sld.cu/index.php/rpan/article/view/

  4. Postuma RB, Poewe W, Litvan I, Lewis S, Lang AE, Halliday G, et al. Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2018;33(10):1601-8.

  5. Díaz Hung ML. Ética en las neurociencias. La investigación con células madre en la enfermedad de Parkinson. Rev Panorama. Cuba y Salud [Internet]. 2019 [citado]; 14(1):68-76-. Disponible en: http://www.revpanorama.sld.cu/index.php/rpan/article/view/

  6. Saracchi E, Fermi S, Brighina L. Emerging candidate biomarkers for Parkinson’s disease: a review. Aging Dis. 2014;5(1):27-34. doi: 10.14366/ AD.2014.050027.

  7. Bu X, Wang X, Xiang Y, Shen L, Wang Q, Liu Y, et al. The association between infectious burden and Parkinson’s disease: A case-control study. Parkinsonism and Related Disorders. 2015. http://dx.doi.org/10.1016/j.parkreldis.2015.05.015.

  8. Díaz M, González M. El estrés oxidativo en las enfermedades neurológicas: ¿causa o consecuencia? [Oxidative stress in neurological diseases: Cause or effect?]. Neurologia. 2014; 29 (8): 451- 452.

  9. Mandal PK, Tripathi M and Sugunan S. Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem. Biophys. Res. Commun. 2012; 417:43-48.

  10. Marín D, Carmona H, Ibarra M, Gámez M. Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento [Parkinson disease: pathophysiology, diagnosis and treatment]. Rev Univ Ind Santander Salud. 2018; 50(1): 79-92. doi: 10.18273/revsal. v50n1-2018008.

  11. Palella S, Martins F. Metodologia de la investigación cuantitativa. 3ra Ed. Caracas: FEDUPEL; 2010.

  12. Niedzielska E, Smaga I, Gawlik M, Oniczewski A, Stankowicz P, Pera J, Filip M. Oxidative Stress in Neurodegenerative Diseases. Molecular Neurobiology. 2016; 53: 4094-4125. DOI 10.1007/s12035-015-9337-5

  13. González Fraguela, ME. Ética en las neurociencias. La contribución del estrés oxidativo en los procesos de aprendizaje y memoria. Rev Panorama. Cuba y Salud [Internet]. 2019 [citado]; 14(1):77-85. Disponible en: http://www.revpanorama.sld.cu/index.php/rpan/ article/view/

  14. Romero Cabrera Á, Amores-Hernández L. El envejecimiento oxidativo inflamatorio: una nueva teoría con implicaciones prácticas. Medisur. 2016; 14(5):1-9. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/3280

  15. De la Fuente M. Role of the immune system in aging. Inmunología. 2008; 27 (4): 176-191. DOI: 10.1016/S0213-9626(08)70066-0

  16. Kalia L, Lang A. Parkinson´s Disease. The Lancet. 2015; 386 (9996): 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3

  17. Fernández J, Granados I, Mejía L, Vergara O, Aviles C. Fattori di Rischio del Morbo di Parkinson: Letteratura scientifica comparata alle cartelle cliniche. Italian Journal of Prevention, Diagnostic and Therapeutic Medicine (IJPDTM). 2019; 2(2): 23 – 34.

  18. Kalia L, Lang A. Evolving basic, pathological and clinical concepts in PD. Nature Reviews Neurology. 2016; 12: 65-66. https://doi.org/10.1038/ nrneurol.2015.249

  19. Coppede F. Genetics and Epigenetics of Parkinson´s Disease. The Scientific World Journal. 2012; 2012: 1-12. doi:10.1100/2012/489830

  20. Gao H, Hong J. Gene–environment interactions: Key to unraveling the mystery of Parkinson’s disease. Progress in Neurobiology. 2011; 94: 1-19.

  21. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: Why is advancing age the biggest risk factor? Ageing Research Reviews. 2014; 14: 19 – 30.

  22. Miyake Y, Sasaki S, Tanaka K. Dietary fat intake and risk of Parkinson’s disease: A case-control study in Japan. Journal of the Neurological Sciences. 2010; 288: 117- 122.

  23. González Hernández T, Cruz-Muros I, Afonso-Oramas D, Salas-Hernandez J, Castro-Hernandez J. Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease. Frontiers in Neuroanatomy. 2010;4 (140): 1-14 https://doi.org/10.3389/fnana.2010.00140

  24. Díaz Hung M, González M, Blanco L. El sistema antioxidante del glutatión en la etiopatología de la disfunción nigro-estriatal. Revista Cubana de Investigaciones Biomédicas. 2015; 34(2):168-186

  25. Garcia González P, Cabral-Miranda F, Hetz C, Osorio F. Interplay Between the Unfolded Protein Response and Immune Function in the Development of Neurodegenerative Diseases. Frontiers in immunology. 2018; 9:2541.

  26. Obeso J, Rodríguez M, Goetz C, Marin C, Kordower J, Rodriguez M, et al. Missing pieces in the Parkinson’s disease puzzle. Nature Medicine. 2010; 16(6):653–661. DOI: 10.1038/nm.2165

  27. Campdelacreu J. Enfermedad de Parkinson y enfermedad de Alzheimer: factores de riesgo ambientales [Parkinson’s disease and Alzheimer disease: environmental risk factors]. Neurología. 2014; 29 (9): 541 – 549.

  28. Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiology of disease. 2018; 109:249-57.

  29. Kaur D, Lee D, Ragapolan S, Andersen JK. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson’s disease. Free Radic Biol Med. 2009;46(5):593-598.

  30. Lee P, Liu L, Sun Y, Chen Y, Liu C, Li C, et al. Traffic-related air pollution increased the risk of Parkinson’s disease in Taiwan: A nationwide study. Environment International. 2016; 96: 75 – 81.

  31. Hong C, Huang Y, Liu H, Chiou H, Chan L, Chien LNewly Diagnosed Anemia Increases Risk of Parkinson´s disease: A Population-Based Cohort Study. Scientific Reports. 2016: 1-7.

  32. Halfon M. Patogénesis de la Enfermedad de Parkinson. Sociedad Neurológica Argentina. 2017. Disponible en: http://www.sna.org.ar/web/ admin/art_doc/172/Patogenesis_de_la_enfermedad_de_Parkinson.pdf

  33. Li D, Song X, Huang H, Huang H, Ye Z. Association of Parkinson’s disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α. Neuroscience letters. 2018; 683:181-4.

  34. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease the gut brain axis and environmental factors. Nature Reviews Neurology. 2015; 11: 625 - 636. https://doi.org/10.1038/nrneurol.2015.197

  35. Wang X, Michaelis E. Selective neuronal vulnerability to oxidative stress in the brain. Front Ag Neurosci. 2010; 12:12.

  36. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson’s disease: A Danish nationwide cohort study 1977–2014. Gut.2019; 68:18-24. doi:10.1136/gutjnl-2017-315666

  37. Houser M, Tansey M. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinson´s Disease. 2017;3: 1-9. doi:10.1038/s41531-016-0002-0

  38. Braak H, de Vos R , Bohl J , Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neuroscience Letter. 2006; 396 (1): 67-72. DOI:10.1016/j.neulet.2005.11.012

  39. Brudek T. Inflammatory Bowel Diseases and Parkinson’s Disease. Journal of Parkinson’s Disease. 2019; 9 (s2): S331-S334. DOI:10.3233/ JPD-191729

  40. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. The Lancet Neurology. 2014; 14: 57-64. https://doi.org/10.1016/S1474-4422(14)70287-X

  41. Walter U, Kleinschmidt S, Rimmele F, Wunderlich C, Gemende I, Benecke R, et al. Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson’s disease. Journal of Neurology. 2013; 260 (12): 3077-85. DOI:10.1007/s00415-013-7125-6

  42. Postuma R, Gagnon J, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Movement Disorders. 2013; 28 (5): 597-604. DOI:10.1002/mds.25445

  43. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience. 2017;18 (7):435-450. doi:10.1038/nrn.2017.62

  44. Clairembault T, Visonneau L, Neunlist M, Derkinderen P. Enteric glial cells: New players in Parkinson’s disease?. Movement Disorders. 2015;30 (4): 494-498. https://doi.org/10.1002/mds.25979

  45. Friedland R. Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration. Journal of Alzheimer’s Disease. 2015; 45: 349- 362. DOI: 10.3233/JAD-142841

  46. Toro G, Sierra U, Gómez L. Prion Theory- Prion Diseases. Acta Neurológica colombiana. 2015; 31: 101-112.




2020     |     www.medigraphic.com